Apidel SA

Apidel SA is an early-stage, privately-funded Swiss pharmaceutical company based in Geneva. Founded in 2011 by two University of Geneva researchers and an experienced industry executive, Apidel specializes in providing proprietary drug delivery solutions which enable more effective, safer and cost effective therapeutic products, which also help patients adhere to their prescribed medical treatment. Apidel’s proprietary technologies allow effective drugs, new and established, to be formulated into new pharmaceutical products with increased therapeutic potential. This provides a platform for new indications, even for established drug molecules. Apidel develops an internal pipeline of products utilizing approved pharmaceuticals and engages with pharmaceutical partners for joint development of products in various fields. All drugs formulated using Apidel’s proprietary technologies enjoy proprietary status under Apidel’s growing portfolio of granted patents and patent applications. By applying its technology to previously approved drug molecules, Apidel expects to accelerate the development and lower the clinical and regulatory risk of its product developments. By partnering, Apidel is able to generate revenue at pre-market stage and thereby increase shareholder value by ensuring an extensive pipeline of products. Apidel’s name is derived from API (Active Pharmaceutical Ingredient) DELivery, which is our primary expertise. Indeed, Apidel’s technical experience in pharmaceutical formulation and in effective drug delivery using polymeric vehicles is unrivalled.

Documedica S.A.

DOCUMEDICA S.A. is a young and dynamic pharmaceutical Swiss company situated on the banks of Lake of Lugano. Documedica is regularly inspected and approved by Swissmedic and is also regularly inspected by notified bodies such as Istituto Superiore di Sanità, Cermet and DNV for Medical Devices with CE marking and quality system. Documedica is a complete partner, capable of starting from the research and development of a finished product, be it drug, medical device, dietary supplement or cosmetic, up to industrial production and it also deals with regulatory issues related to the registration or certification of a product. Documedica avails itself of qualified distributors for the distribution of its products around the world. Born in 2002, Documedica has in the pipeline 5 CE marked medical devices, 4 dietary supplements and 10 cosmetic products already distributed in some countries within and outside Europe. Documedica is a company that is not afraid of novelty and continues to invest in research and development of innovative products.

Centre de Diagnostic Radiologique de Carouge

Equinox Pharma Ltd

Equinox Pharma is a computationally-driven logic-based drug discovery company which, in partnership with pharma companies, agrochemical companies, biotechs and medicinal chemistry-based contract research organizations, uses its capability in proprietary logic-based machine learning and chemoinformatics (INDDEx™), based on the patented SV-ILP method (Patent number 8126823), to undertake drug discovery programmes for its clients. Equinox Pharma uses its proprietary logic-based machine-learning technique INDDEx™ (Investigational Novel Drug Discovery by Example) to learn from a training dataset of active and inactive molecules from a screening programme to generate quantitative logic-based rules. These rules provide vital chemical insight into the stereochemical and structural requirements for biological activity. Equinox then undertakes ligand-based virtual screening using the logic-based rules to search databases of commercially available, or proprietary, libraries of small molecules to identify potentially active molecules In contrast to other database screening tools, INDDEx™ is unique in the approach used such that the new structures identified, and predicted to be active, can bear little resemblance to the training data molecules. In this way INDDEx™ is a leading tool in scaffold-hopping technology. Reynolds, et al (2012). Assessment of a Rule-Based Virtual Screening Technology (INDDEx) on a Benchmark Data Set. J Phys Chem B 116, 6732-9.

Fagron Australia

Fagron's mission is to optimise and innovate personalised pharmaceutical care. Fagron is a multinational and publicly listed pharmaceutical company, founded in the Netherlands (Rotterdam) in 1990. Through a continuous focus on innovation, quality and solution-oriented thinking, Fagron obtained market leadership in pharmaceutical compounding. Fagron Australia is an affiliate of the multinational, located in Sydney. The company supplies pharmaceutical raw materials, equipment and innovative bases and suspending vehicles to compounding pharmacies all over Australia, New Zealand and South East Asia. Fagron Compounding Supplies Australia is fully compliant with TGA Good Wholesaling Practices and is licensed by the TGA to import restricted and controlled substances. Follow us on Twitter: @FagronAU Like us on Facebook: FagronAU Follow us on Instagram: @fagronau